Deadline: 23-Jul-25
The Pfizer is requesting applications for optimizing the experience of patients with bladder cancer through multi-disciplinary care.
Scopes
- Proposals are encouraged that address improving the patient experience and management of care throughout the bladder cancer continuum, from diagnosis to survivorship, with a specific focus on the coordination of the multi-disciplinary care of patients. This includes using established quality improvement approaches to close known gaps related to:
- Improved shared decision making and communication across all stakeholders along the care journey (multi-disciplinary teams, providers, and patients).
- Optimized coordination of care, including helping patients navigate their own care journey.
- Guideline(s) concordance, optimizing implementation of care and mitigating complications to improve patient outcomes.
- Providing solutions for delivering quality multi-disciplinary care for both providers and patients in diverse practice settings.
- Ensuring safe and consistent therapeutic management to optimize treatment for all patients with bladder cancer.
- Utilizing technology (data science, patient centered mobile app or AI) to improve the ease of navigating the bladder cancer treatment paradigm.
Areas of Interest
- It is their intent to support quality improvement projects in the US, that focus on improving the multi-disciplinary care, and outcomes, of patients with bladder cancer throughout the care continuum (diagnosis stage, NMIBC, MIBC, and mUC).
- Collaborations with other practices and institutions are encouraged when appropriate, but all partners must have a relevant role defined in the proposal. Collaborators should provide a letter of support.
- It is expected that projects will be evidence-based, and the proposed research/evaluation will follow generally accepted scientific principles. During review the intended outcome of the project is given careful consideration and, if appropriate, based on the project goal, projects with the maximum likelihood of directly impacting patient care will be given high priority.
Funding Information
- This opportunity is intended to support quality improvement projects with an 18-24 month duration, and a maximum budget of $250,000.
- The estimated total available budget related to this RFP is $1.5 million. Exceptional proposals with multiple significant collaborating organizations and the potential for wide expansion beyond a single health system may request up to $1 million.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved and will be stated clearly in the grant agreement.
Target Audience
- Target applicants include medical, surgical, and radiation oncologists, urologists, nurses, advanced practice providers and other members of the multi-disciplinary team treating patients with bladder cancer in diverse settings (including academic and community settings).
- Target population are adult patients across all stages of bladder cancer, including NMIBC, MIBC, and unresectable locally advanced or mUC. This may include patients being diagnosed with bladder cancer (e.g. those evaluated for hematuria).
Eligibility Criteria
- Community clinics treating patients with bladder cancer are highly encouraged to apply.
- The following institutions may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); independent practice groups; professional organizations; government agencies; and other entities with a mission related to healthcare improvement.
- Only organizations and independent practice groups are eligible to receive grants, not individual professionals or solo practices.
- The primary applicant must be US based. However, collaborative sites outside the US are permissible.
- Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI’s grant/research coordinator).
- The Project Lead/PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. They strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.
- For projects offering continuing education credit, the requesting organization must be accredited.
For more information, visit Pfizer.
